|1.||Mansour, Tarek S: 2 articles (01/2012 - 03/2010)|
|2.||Yang, Yuan: 1 article (08/2015)|
|3.||He, Xi-Xin: 1 article (08/2015)|
|4.||Huang, Zhi-Shu: 1 article (08/2015)|
|5.||An, Lin-Kun: 1 article (08/2015)|
|6.||Wei, Hong-Yu: 1 article (08/2015)|
|7.||Li, Xiao-Bing: 1 article (08/2015)|
|8.||Gu, Lian-Quan: 1 article (08/2015)|
|9.||Yu, Le-Mao: 1 article (08/2015)|
|10.||Zhang, Xiao-Ru: 1 article (08/2015)|
07/12/2007 - "Compound 26 also strongly inhibited the growth of matched tumor cells, KB-VIN and its parent cell KB. Furthermore, analogs 13 and 21 were over 5-fold more potent against KB-VIN than KB. Bromination of ring-B and tripropyl functionalization of ring-A enhanced activity, while alkylation of ring-B promoted KB-VIN/KB selectivity. "
08/14/2014 - "Finally, selected compound 26 was found to exhibit obvious in vivo antitumor activity in A549 tumor xenografts model. "
10/15/2013 - "Many of these compounds exhibited nanomolar antiproliferation activities against human tumor lines in in vitro cell culture experiments, and a representative example (compound 26) demonstrated encouraging in vivo efficacy in a mouse xenograft tumor model derived from the A2780 cell line. "
03/25/2010 - "Compound 26 has shown excellent activity in vitro and in vivo, with antitumor efficacy in both subcutaneous and orthotopic xenograft tumor models when administered intravenously. "
11/14/2013 - "Furthermore, compound 26 effectively reduced the tumor growth bared by human gastric cancer cells in vivo with no signs of adverse side effects. "
01/01/2005 - "Chemotherapeutic activity of 3-(5-nitrofuryl)-7-(5-nitrofurfuryliden)-3, 3a, 4, 5, 6, 7-hexahydro-2H-indazol (compound 26) was studied on albino mice with experimental staphylococcal infection. "
01/01/2005 - "[Chemotherapeutic effect of 3-(5-nitrofuryl)-7-(5-nitrofurfurylidene)-3,3a,4,5,6,7-hexahydro-2H-indazole in experimental staphylococcal infection]."
01/01/2005 - "The results showed that compound 26 in a dose 20 mg/kg (0.4 mg/mouse) possessed high chemotherapeutic activity in experimental staphylococcal infection of albino mice and could be recommended for a thorough study as a potential agent for chemotherapy of staphylococcal infection."
01/01/2009 - "Seven compounds, 1, 6, 9, 10, 18, 20, and 26, on evaluation for their inhibitory effect against 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced inflammation (1 microg/ear) in mice, exhibited, except for compound 26, marked anti-inflammatory activity (ID(50) values 0.09-0.26 mg/ear). "
01/01/2012 - "Compound 26 (MMP118), which exhibits excellent oral efficacy in the MMP-12 induced ear-swelling inflammation and lung inflammation mouse models, had been successfully advanced into Development Track status."
12/23/2010 - "Furthermore, compound 26 displays promising effects by interfering with CXCR4 function in three mouse models: paw inflammation, Matrigel plug angiogenesis, and uveal melanoma micrometastasis. "
12/15/2010 - "The most promising compound 26 showed around 30-fold more selectivity towards C33A (cervical carcinoma) cells over normal fibroblast NIH3T3 cells with an IC(50) value of 3.59 μM."
04/30/1993 - "These compounds demonstrated the most marked effects in the screen on two colon carcinoma cell lines (COLO-205 and KM-20L2) and on a central nervous system tumor cell line (SF-539) with compound 26 the most potent of the three agents. "
|5.||Venous Thrombosis (Deep-Vein Thrombosis)
|1.||Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)
|8.||K 76 carboxylic acid
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)